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Background: Gallstone disease is one of the most common digestive disorders, affecting more than 30 million
Americans. Previous twin studies suggest a heritability of 25% for gallstone formation. To date, one genome-wide
association study (GWAS) has been performed in a population of European-descent. Several candidate gene studies
have been performed in various populations, but most have been inconclusive. Given that gallstones consist of up
to 80% cholesterol, we hypothesized that common genetic variants associated with high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) would also be associated with
gallstone risk.
Methods: To test this hypothesis, the Epidemiologic Architecture for Genes Linked to Environment (EAGLE) study
as part of the Population Architecture using Genomics and Epidemiology (PAGE) study performed tests of
association between 49 GWAS-identified lipid trait SNPs and gallstone disease in non-Hispanic whites (446 cases
and 1,962 controls), non-Hispanic blacks (179 cases and 1,540 controls), and Mexican Americans (227 cases and
1,478 controls) ascertained for the population-based Third National Health and Nutrition Examination Survey
(NHANES III).
Results: At a liberal significance threshold of 0.05, five, four, and four SNP(s) were associated with disease risk in
non-Hispanic whites, non-Hispanic blacks, and Mexican Americans, respectively. No one SNP was associated with
gallstone disease risk in all three racial/ethnic groups. The most significant association was observed for ABCG5
rs6756629 in non-Hispanic whites [odds ratio (OR) = 1.89; 95% confidence interval (CI) = 1.44-2.49; p = 0.0001). ABCG5
rs6756629 is in strong linkage disequilibrium with rs11887534 (D19H), a variant previously associated with gallstone
disease risk in populations of European-descent.
Conclusions: We replicated a previously associated variant for gallstone disease risk in non-Hispanic whites. Further
discovery and fine-mapping efforts in diverse populations are needed to fully describe the genetic architecture of
gallstone disease risk in humans.
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Gallstone disease has become one of the most common
digestive disorders in the world. Gallstone disease affects
more than 30 million Americans and accounts for
750,000 gallbladder removals in the United States annu-
ally and at least 190,000 gallbladder removals in
European countries such as Germany [1]. The preva-
lence of gallstone disease varies by race/ethnicity with
Native Americans and Hispanics having the highest re-
ported prevalence compared with populations of Euro-
pean or African descent [2-7]. The incidence and
prevalence is likely under-estimated given the fact that
up to 80% of individuals with gallstones are asymptom-
atic or have non-traditional symptoms of disease [8].
There are a number of well-established gallstone disease
risk factors including older age, female sex, increased body
mass index, race/ethnicity, and certain dietary habits such
as consumption of food rich in refined carbohydrates and
lipids [1,9-13]. In addition to the established demographic
and lifestyle risk factors, there is evidence that gallstone dis-
ease risk has a significant genetic component. Family his-
tory of gallstone disease increases an individual’s risk for
the same disease [8,14,15]. Twin studies suggest that up to
25% of the risk of gallstone disease is due to genetic factors
[16]. Indeed, recent candidate gene [17-19] and genome-
wide association (GWA) [20] studies along with linkage
studies [21] have identified common genetic variants asso-
ciated with gallstone disease risk.
The majority of gallstones are composed of condensed
bile components containing up to 80% cholesterol
(termed “cholesterol gallstones”) [13]. Based on the com-
position of gallstones and recent results from genetic as-
sociation studies, we hypothesized that common genetic
variants associated with lipid profiles would be associ-
ated with gallstone disease risk. To test this hypothesis,
we conducted a genetic association study for gallstone
disease and 49 genetic variants previously associated
with high-density lipoprotein cholesterol (HDL-C), low
density lipoprotein cholesterol (LDL-C), and triglycer-
ides (TG) [22] in the diverse Third National Health and
Nutrition Examination Survey (NHANES III) as part of
the Epidemiologic Architecture for Genes Linked to En-
vironment (EAGLE) study [23]. Overall, we observed
thirteen associations between gallstone disease and lipid-
associated variants among the three racial/ethnic groups
at a liberal significance threshold of 0.05 with the most
significant association observed for ABCG5 rs6756629 in
non-Hispanic whites (OR = 1.89; 95% CI: 1.44-2.49).
ABCG5 rs6756629 has been previously associated with
lipid profiles (LDL-C, total cholesterol, and triglycerides)
and is in strong linkage disequilibrium with ABCG5
rs112887534 in European-descent populations [24], a
variant recently associated with gallstone disease [20].
Collectively, our data support the hypothesis that geneticvariation associated with lipid trait variation is also asso-
ciated with gallstone disease risk.
Methods
Study population and phenotypes
The study population described here includes phase 2 par-
ticipants ascertained between 1991 and 1994 as part of the
Third National Health and Nutrition Examination Survey
(NHANES III). NHANES is now conducted yearly by the
National Center on Health Statistics (NCHS) at the Center
for Disease Control and Prevention (CDC) with the major
goal of assessing the health and nutrition status of Ameri-
cans regardless of health status. Beginning with NHANES
III phase 2, CDC began collecting bio-specimens from con-
senting participants for genetic studies. NHANES is a com-
plex survey design that oversamples specific age groups
(such as the elderly) and racial/ethnic groups (such as non-
Hispanic blacks).
All eligible participants were given an approximately
hour long interview. Participants also underwent a
health examination by the Mobile Exam Centers (MEC),
and blood and urine samples were also obtained [25].
Participants were eligible for NHANES at two months of
age or older, while participants consenting for bio-
specimen collection for DNA extraction had to be at
least twelve years of age. Non-eligible individuals in-
cluded military personnel and institutionalized civilians.
Genetic NHANES III includes 7,159 participants, of
which 2,631 are self-described non-Hispanic white,
2,108 are self-described non-Hispanic black, and 2,073
are self-described Mexican American. All procedures
were approved by the CDC Ethics Review Board and
written informed consent was obtained from all partici-
pants. Because no identifying information was accessed
by the investigators, Vanderbilt University’s Institutional
Review Board determined that this study met the criteria
of “non-human subjects.”
Gallstones were defined by a positive “yes” response to
an administered questionnaire exam asking, “Has the
doctor ever told you that you had gallstones?” or a posi-
tive ultrasound reading (presence of scar tissue (surgical
removal of gallbladder or cholecystectomy) or demon-
stration of gallstones present in the gallbladder) from
trained technicians. Controls were defined as gallstone-
free participants who answered “no” response to the ad-
ministered questionnaire or had no history of gallstone
removal surgeries. To assess the potential for misclassifi-
cation, we examined participants with both ultrasound
and questionnaire data to validate asymptomatic cases
and to identify misclassified controls.
SNP selection and genotyping
A total of 49 GWAS-identified SNPs were selected for
study based on evidence of being previously associated
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published candidate gene and genome-wide association
studies [10,12,18,20,22]. The SNP selection criteria meet
the genome-wide significance of p < 10−8 in previous
published studies [22]. SNP data was generated by geno-
typing using Sequenom and Illumina BeadXpress plat-
forms. Thorough genotyping and SNP details (gene
region, physical location, coding type, etc.) have been
previously published in Text S1 of [22]. CDC quality
control metrics were implemented on the 49 SNPs and
included tests of Hardy-Weinberg Equilibrium (thresh-
old of p > 0.0001 in at least two of the three race/ethnici-
ties) as well as concordance with blinded duplicates
supplied by CDC (at least 95%). Also, as part of the
PAGE study [23], we genotyped these lipid-associated
SNPs in 360 HapMap samples for network-wide quality
control assessment.
Statistical methods
Participants less than 18 years of age were excluded
from this study. Single SNP tests of association were
performed using logistic regression. Gallstone status
(yes/no) was the dependent variable and each SNP as-
suming an additive genetic model was the independent
variable. All models were adjusted for age, sex, and body
mass index. Logistic regressions were performed strati-
fied by self-reported race/ethnicity, and genetic effect es-
timates were expressed as odds ratios (ORs) with 95%
confidence intervals (95% CIs). All analyses were con-
ducted in SAS v9.2 (SAS Institute, Cary, NC) using the
Analytic Data Research by Email (ANDRE) portal of the
CDC Research Data Center in Hyattsville, MD. Results
were plotted using Synthesis-View [26]. Linkage disequi-




Study population characteristics by self-described race/
ethnicity and gallstone disease status are given in Table 1.Table 1 Study population characteristics by gallstone disease
Non-hispanic whites No
n = 2,408
Cases Controls P-value Cases
n 446 1,962 - 179









(kg/m2) (6.1) (5.35) 6.67)
Abbreviations: BMI body mass index.
Means (and standard deviations) are given unless otherwise noted. P-values were cOverall, we identified 446, 179, and 227 cases of gall-
stone disease among non-Hispanic whites, non-Hispanic
blacks, and Mexican Americans, respectively. As ex-
pected, based on the known epidemiology of gallstone
disease [3,13], cases tended to be female, older, and have
a higher BMI compared with controls (Table 1). Also,
overall, there were proportionally fewer cases among
non-Hispanic blacks compared with non-Hispanic
whites and Mexican Americans, which is consistent with
the lower prevalence of this disease among this group
[3].
Among the 49 lipid trait-associated SNPs tested for as-
sociation with gallstone disease, five, four, and four SNPs
were associated with disease risk at a liberal signifi-
cance threshold of 0.05 among non-Hispanic whites,
non-Hispanic blacks, and Mexican Americans, respect-
ively (Table 2; Additional file 1: Table S1). Among all
groups, the most significant finding was observed in
non-Hispanic whites (OR = 1.89; 95% CI = 1.44-2.49;
p = 0.0001) for non-synonymous ABCG5 rs6756629, a
variant whose minor allele (A) was previously associated
with decreased LDL-C and total cholesterol and in-
creased triglycerides among European-descent popula-
tions [28]. This associated SNP is in strong linkage
disequilibrium with ABCG5 rs11887534 identified in a
genome-wide association within a European-descent
population for gallstone disease [20,24]. The second as-
sociation identified for gallstone disease in non-Hispanic
whites involved ABCG8 rs6544713 (OR = 1.35; 95% CI =
1.14-1.61; p = 0.0007), a variant previously associated
with LDL-C levels in European-descent populations [29].
ABCG8 rs6544713 is not in linkage disequilibrium with
rs6756629 or rs11887534 (both r2 = 0.047 in CEU 1000
Genomes Project) and therefore most likely represents
an independent association with gallstone disease risk.
Interestingly, despite the smaller sample size, four as-
sociations at p < 0.05 were observed among non-
Hispanic blacks. The most significant finding among
non-Hispanic blacks was BUD13 rs28927680 (OR = 1.40;
95% CI = 1.06-1.86, p = 0.019) previously associated withstatus stratified by race/ethnicity
n-hispanic blacks Mexican Americans
n = 1,719 n = 1,708
Controls P-value Cases Controls P-value
1,540 - 227 1,478 -











alculated based on the Wald test using unweighted survey data.
Table 2 Significant tests of association for gallstone disease by population
SNPs Gene OAT Non-Hispanic Whites Non-Hispanic Blacks Mexican Americans
Case/ Control CAF OR (95% C.I.) P Case/ Control CAF OR (95% C.I.) P Case/ Control CAF OR (95% C.I.) P
rs10401969 SUGP1 TG § 1.37 (1.05, 1.78) 1.89E-02 § 1.01 (0.74, 1.38) 9.61E-01 § 0.69 (0.41, 1.15) 1.52E-01
rs10889353 DOCK7 TG 0.64/ 0.67 0.90 (0.76, 1.05) 1.83E-01 0.61/ 0.62 0.84 (0.67, 1.06) 1.50E-01 0.66/ 0.62 1.32 (1.05, 1.67) 1.73E-02
rs17216525 CILP2 TG § 0.76 (0.58, 0.99) 4.45E-02 § 1.26 (0.64, 2.46) 5.02E-01 § 0.88 (0.53, 1.45) 6.15E-01
rs1883025 ABCA1 HDL 0.27/ 0.26 1.09 (0.92, 1.30) 3.36E-01 0.30/ 0.33 0.84 (0.66, 1.09) 1.86E-01 0.26/ 0.28 0.78 (0.62, 0.98) 3.30E-02
rs2650000 HNF1A LEF1 LDL 0.66/ 0.65 1.146 (0.97, 1.35) 1.02E-01 § 1.50 (1.02, 2.21) 3.73E-02 0.63/ 0.63 0.976 (0.79, 1.20) 8.21E-01
rs28927680 BUD13 HDL TG 0.09/ 0.07 1.23 (0.93, 1.62) 1.53E-01 0.22/ 0.17 1.40 (1.06, 1.86) 1.92E-02 0.16/ 0.14 1.07 (0.81, 1.42) 6.27E-01
rs3764261 CETP HDL 0.68/ 0.68 0.95 (0.80, 1.12) 5.15E-01 0.63/ 0.69 0.71 (0.56, 0.90) 4.70E-03 0.66/ 0.66 1.06 (0.85, 1.33) 5.89E-01
rs4149268 ABCA1 HDL 0.38/ 0.38 1.10 (0.94, 1.30) 2.34E-01 0.69/ 0.65 1.03 (0.81, 1.31) 8.21E-01 0.30/ 0.33 0.75 (0.60, 0.95) 1.53E-02
rs4939883 LIPG HDL 0.83/ 0.83 1.28 (1.03, 1.59) 2.71E-02 0.56/ 0.54 0.94 (0.75, 1.19) 6.17E-01 § 0.88 (0.65, 1.19) 4.14E-01
rs6544713 ABCG8 LDL 0.71/ 0.68 1.35 (1.14, 1.61) 7.00E-04 § 1.19 (0.88, 1.62) 2.65E-01 0.85/ 0.82 1.22 (0.92, 1.60) 1.66E-01
rs6756629 ABCG5 LDL 0.09/ 0.06 1.89 (1.44, 2.49) 1.00E-04 0.13/ 0.08 1.24 (0.82, 1.87) 3.03E-01 0.12/ 0.09 1.19 (0.85, 1.67) 3.04E-01
rs754523 APOB LDL 0.33/ 0.32 1.02 (0.86, 1.20) 8.34E-01 0.27/ 0.22 1.36 (1.04, 1.78) 2.41E-02 0.24/ 0.29 0.86 (0.68, 1.08) 1.82E-01
rs7679 PCIF1 HDL 0.19/ 0.16 0.97 (0.79, 1.19) 7.45E-01 § 1.18 (0.75, 1.84) 4.73E-01 0.14/ 0.11 1.51 (1.13, 2.01) 4.80E-03
Single SNP tests of association were performed using logistic regression assuming an additive genetic model. Only results for SNPs associated at p < 0.05 in any one race/ethnicity are shown (bolded and italicized).
Results displayed here were adjusted for age, sex, and body mass index. §Per data use agreement, coded allele frequencies are not outputted by CDC for cells with ≤5 counts.





















Goodloe et al. BMC Medical Genetics 2013, 14:120 Page 5 of 9
http://www.biomedcentral.com/1471-2350/14/120HDL-C and TG in European-descent populations [29].
Other nominal associations observed in non-Hispanic
blacks included genetic variants previously associated
with HDL-C (CETP rs3764261 (OR = 0.71; 95% CI 0.56-
0.9)) and LDL-C (HNF1A/LEF1 rs2650000 (OR = 1.50;
95% CI 1.02-2.21) and APOB rs754523 (OR = 1.36;
95% CI 1.04-1.78)).
Among Mexican Americans, four associations were nom-
inally associated with gallstone disease risk: HDL-C
(ABCA1 rs1883025 (OR = 0.78; 95% CI 0.62-0.98;
p = 0.033), ABCA1 rs4149268 (OR = 0.75; 95% CI 0.60-0.95;
p = 0.015), and PCIF1 rs7679 (OR= 1.51; 95% CI 1.13-2.01;
p = 0.048)) and TG (DOCK7 rs10889353 (OR= 1.23; 95%Figure 1 Associations between HDL-C associated SNPs and gallstone
ated SNP was tested for an association with gallstone disease (yes/no) assu
index [kg/m2]. The odds ratio and 95% confidence intervals are plotted by
37.5) are given on the y-axis. Each square represents an odds-ratio and eac
larger square represents a significantly associated SNP at p < 0.05. Populatio
Hispanic blacks (red), and Mexican Americans (green). The grey vertical lineCI 1.05-1.67; p = 0.017). No association was associated at
p < 0.05 across all three racial/ethnicity groups (Table 2).
In addition to examining genetic associations for gall-
stone disease risk by race/ethnicity, we also examined
the associations by associated lipid trait (Figures 1, 2 and
3; Additional file 2: Figure S1). That is, among the 49
SNPs tested here, 24, 14, and 17 SNPs were reported to
be associated with HDL-C, LDL-C, and TG levels, re-
spectively. As previously mentioned, the most significant
finding involved an LDL-C associated variant, and, over-
all, approximately one-third (4 out of 14 or 29%) of
LDL-C associated SNPs were nominally associated with
gallstone disease risk in any one population. The otherdisease by population. Each high-density lipoprotein (HDL)-associ-
ming an additive genetic model adjusted for age, sex, and body mass
race-ethnicity using Synthesis-View [26]. SNP locations (genome build
h line represents a 95% confidence interval for each population. The
ns are color-coded as follows: non-Hispanic whites (blue), non-
represents the 1.0 threshold for odds-ratio values.
Figure 2 Associations between LDL-C associated SNPs and gallstone disease by population. Each low-density lipoprotein (LDL)-associated
SNP was tested for an association with gallstone disease (yes/no) assuming an additive genetic model adjusted for age, sex, and body mass index
[kg/m2]. The odds ratio and 95% confidence intervals are plotted by race-ethnicity using Synthesis-View [26]. SNP locations (genome build 37.5)
are given on the y-axis. Each square represents an odds-ratio and each line represents a 95% confidence interval for each population. The larger
square represents a significantly associated SNP at p < 0.05. Populations are color-coded as follows: non-Hispanic whites (blue), non-Hispanic
blacks (red), and Mexican Americans (green). The grey vertical line represents the 1.0 threshold for odds-ratio values.
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with HDL-C (6 out of 24 or 25%) or triglycerides (4 out
of 17 or 24%) associated SNPs.
Discussion
Among the 49 lipid-trait associated SNPs tested here,
thirteen were associated with gallstone disease risk at a
liberal significance threshold of 0.05 in at least one ra-
cial/ethnic group. Most (5/13; 38%) associations were
observed among non-Hispanic whites; conversely, four
associations each were identified among non-Hispanic
blacks and Mexican Americans. None of the associations
were observed in all three racial/ethnic groups. The
strongest association for gallstone disease risk was ob-
served in non-Hispanic whites (OR = 1.89; 95% CI: 1.44-
2.49) for ABCG5 rs6756629; although not significant
(p = 0.30), this association trended in the same direction
in non-Hispanic blacks (OR = 1.24; 95% CI 0.82-1.87)
and Mexican Americans (OR = 1.26; 95% CI 0.89-1.79).
Replication in European-descent populations
ABCG5 rs6756629 (R50C) is in strong linkage disequilib-
rium with rs11887534 (D19H), a variant previously asso-
ciated with gallstone disease risk in populations of
European-descent [20]. Pairwise linkage disequilibrium
(r2) was 1.00 in CEU from the 1000 Genomes ProjectPilot Study [30] and 0.95 in a German study population
[24]. Thus, the association observed here with rs6756629
likely represents a replication of the association identi-
fied in the original GWAS [20]. The magnitude of effect
(OR = 1.89) is somewhat smaller compared with the
original (OR = 2.2) [20] and subsequent reports
[18,21,24,31], but the confidence intervals overlap sug-
gesting similar overall genetic effect sizes for this
population.
Associations among non-European-descent populations
Very few genetic association studies and no GWA studies
of gallstone disease risk have been performed in popula-
tions of non-European descent. A few studies have exam-
ined the association between ABCG5 rs11887534 and
gallstone disease in populations from China [24], Taiwan
[32], and India [24]. To our knowledge, no study has exam-
ined ABCG5 rs11887534 or tagged rs6756629 in African
Americans or Mexican Americans for gallstone disease risk.
As expected based on the known epidemiology of gallstone
disease, the sample sizes available for non-Hispanic blacks
(n = 179 cases) and Mexican Americans (n = 227 cases)
were smaller compared with non-Hispanic whites (n = 446
cases). ABCG5 rs6756629 was not associated with gallstone
disease risk in non-Hispanic blacks (Table 2). The ABCG5
variants rs11887534 and rs6756629 have lower pair-wise
Figure 3 Associations between TG associated SNPs and gallstone disease by population. Each triglyceride (TG)-associated SNP was tested
for an association with gallstone disease (yes/no) assuming an additive genetic model adjusted for age, sex, and body mass index [kg/m2]. The
odds ratio and 95% confidence intervals are plotted by race-ethnicity using Synthesis-View [26]. SNP locations (genome build 37.5) are given on
the y-axis. Each square represents an odds-ratio and each line represents a 95% confidence interval for each population. The larger square repre-
sents a significantly associated SNP at p < 0.05. Populations are color-coded as follows: non-Hispanic whites (blue), non-Hispanic blacks (red), and
Mexican Americans (green). The grey vertical line represents the 1.0 threshold for odds-ratio values.
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r2 = 0.613) compared with European-descent populations
(CEU r2 = 1.000) based on data from the 1000 Genomes
Project Pilot Study [30]. Recent statistical and functional
data suggest that ABCG5 rs11887534 (D19H) is likely the
functional variant responsible for the association with gall-
stone disease risk while rs6756629 is likely a tagSNP [24].
The smaller sample sizes available for non-European des-
cent populations coupled with differences in linkage dis-
equilibrium between the genotyped rs6756629 and putative
functional rs11887534 likely resulted in low statistical
power to detect this association in non-Hispanic blacks and
Mexican Americans. Further ABCG5 fine-mapping and
functional studies are needed to fully catalogue gallstone
disease risk variants in diverse populations.
Limitations and strengths
This study has several limitations and strengths. A major
limitation is sample size and power. Although genetic
NHANES III is large overall (n = 7,159), the number of
cases and controls available for this gallstone disease
study is small when stratified by race/ethnicity. Morerecent NHANES did not collect survey or ultrasound
data; therefore, large sample sizes or independent repli-
cation datasets for genetic associations for gallstone dis-
ease risk are not available in NHANES. To maximize the
power of the present study within NHANES III, we used
both questionnaire and ultrasound data (where ultra-
sound data represented the “truth” or gold standard
when both were available per participant) to define cases
and controls. Indeed, limiting the dataset to participants
with both data types would have resulted in a 14% re-
duction in sample size. A trade-off of this approach to
maximize sample size, however, is that we may have
misclassified participants who only had questionnaire
data but no corroborating ultrasound data. To examine
the possible extent of misclassification, we compared
our case/control definition (questionnaire or ultrasound
data) with case/control status among participants with both
data types (excluding those participants with questionnaire
data only). Overall, we found little evidence for misclassifi-
cation using questionnaire data only (positive predictive
value = 99%, negative predictive value = 100%, sensitivity =
100%, and specificity = 99%). We also compared results of
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little difference (Additional file 3: Figure S2).
Another limitation to the study is that we did not ad-
just our significance level for multiple statistical tests.
Our liberal significance threshold coupled with the lack
of an independent dataset can be cause for concerns for
false positive associations. However, the most significant
association reported here replicated an association previ-
ously reported in a GWAS in a population of similar
race/ethnicity. The association between rs6756629 and
gallstone disease risk in non-Hispanic whites, along with
the association involving ABCG5 rs6544713, would be
considered significant with a conservative Bonferroni
correction. The facts that the associations represent a
replication of a previous report [20], that rs6756629 tags
a likely functional SNP associated with gallstone disease
risk [24], and that both survive correction for multiple
testing support the conclusion that these are not a false
positive findings.
A major strength of the current study is its diversity.
Little to no data exist for the genetics of gallstone dis-
ease risk in African Americans and Mexican Americans.
Further discovery studies are needed to identify the full
genetic architecture of gallstone disease risk in diverse
populations [33]. Another major strength of this current
study is the combination of questionnaire and ultra-
sound data available in NHANES III. For participants
with overlapping questionnaire and ultrasound data, we
were able to identify asymptomatic cases of gallstones
that would have otherwise been misclassified using ques-
tionnaire data only. Misclassification of case/control sta-
tus lowers power to detect genetic associations;
therefore, careful phenotyping is one of many essential
components in the conduction of genetic association
studies [34]. Combination of these data types maximized
sample size for this study whereas restricting eligible
cases and controls to participants with ultrasound data
only would have reduced the sample size by 14% and
therefore reduced power.Conclusions
In summary, we demonstrate here that lipid-trait associ-
ated genetic variants such as ABCG5 rs6756629 are as-
sociated with gallstone disease risk. Larger studies of
diverse populations are needed to determine the full
spectrum of the genetic variants that contribute to gall-
stone disease risk in humans.Additional files
Additional file 1: Table S1. All tests of association for gallstone disease
by population. Single SNP tests of association were performed using
logistic regression assuming an additive genetic model. Results displayedhere were adjusted for age, sex, and body mass index. SNP position is
based on genome build 37.5.
Additional file 2: Figure S1. All associations between lipid trait-
associated SNPs and gallstone disease by population. A total of 49 lipid-
trait associated SNPs were tested for an association with gallstone disease
using logistic regression adjusted for age, sex, and body mass index
[kg/m2]. Synthesis-View [26] was used to display the results. SNP location
(genome build 37.5) is given on the x-axis and p-values (−log10
transformed) are plotted along the y-axis at the top of the figure, while
coded allele frequencies (CAF) are plotted along the y-axis at the bottom
of the figure. Each triangle represents a p-value and each circle repre-
sents a CAF for each race-ethnicity. Populations are color-coded as
follows: non-Hispanic whites (blue), non-Hispanic blacks (red), and
Mexican Americans (green). The direction of the arrows corresponds to
the direction of the beta coefficient. The significance threshold is
indicated by the red bar at p = 0.05.
Additional file 3: Figure S2. Assessment of the impact of including
questionnaire data to maximize sample size versus potential
misclassification. A total of 49 lipid-trait associated SNPs were tested for
an association with gallstone disease using logistic regression adjusted
for age, sex, and body mass index [kg/m2]. The analysis was performed
twice where cases and controls were 1) defined by questionnaire or ultra-
sound data and 2) defined by questionnaire and ultrasound data.
Synthesis-View [26] was used to display the results. SNP location (genome
build 37.5) is given on the x-axis and p-values (−log10 transformed) are
plotted along the y-axis for the top of the figure, while case/control totals
are plotted along the y-axis for the bottom of the figure. Each triangle
represents a p-value and each full circle represents a case while each
empty circle represents a control. Triangles are color-coded such that red
represents results from cases and controls defined by questionnaire or
ultrasound data and blue represents results from cases and controls de-
fined by questionnaire and ultrasound data. The direction of the arrows
corresponds to the direction of the beta coefficient. The significance
threshold is indicated by the red bar at p = 0.05.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
RG and DCC designed the study, interpreted the data, and drafted and
edited the manuscript. RG and KB-G conducted the analyses. NBG, HJ, PM,
MA, CS, NS-B, and HHD generated the genetic data and performed quality
control analyses. BM and JB developed the analysis pipeline and maintained
the study databases. All authors have read and approved the final
manuscript.Acknowledgements
Genotyping in NHANES was supported in part by The Population
Architecture using Genomics and Epidemiology (PAGE) study, which is
funded by the National Human Genome Research Institute (NHGRI). Data
included in this report were resulted from the Epidemiologic Architecture for
Genes Linked to Environment (EAGLE) Study, as part of the NHGRI PAGE
study (U01HG004798). Genotyping services for select EAGLE NHANES III SNPs
presented here were also provided by the Johns Hopkins University under
federal contract number (N01-HV-48195) from NHLBI. We at EAGLE would
like to thank Dr. Geraldine McQuillan and Jody McLean for their help in
accessing the Genetic NHANES data. The Vanderbilt University Center for
Human Genetics Research, Computational Genomics Core provided
computational and/or analytical support for this work. The NHANES DNA
samples are stored and plated by the Vanderbilt DNA Resources Core. The
findings and conclusions in this report are those of the authors and do not
necessarily represent the views of the National Institutes for Health or the
Centers for Disease Control and Prevention.
Received: 23 May 2013 Accepted: 22 October 2013
Published: 21 November 2013
Goodloe et al. BMC Medical Genetics 2013, 14:120 Page 9 of 9
http://www.biomedcentral.com/1471-2350/14/120References
1. Krawczyk M, Rusticeanu M, Grunhage F, Mahler M, Portincasa P, Acalovschi M,
Lammert F: Analysis of the common vasoactive intestinal peptide receptor 1
polymorphism in gallstone patients. J Gastrointest Liver Dis 2010, 19:273–277.
2. Mendez-Sanchez N, King-Martinez AC, Ramos MH, Pichardo-Bahena R, Uribe
M: The Amerindian's Genes in the Mexican Population are Associated
with Development of Gallstone Disease. Am J Gastroenterol 2004,
99:2166–2170.
3. Everhart JE, Khare M, Hill M, Maurer KR: Prevalence and ethnic differences
in gallbladder disease in the United States. Gastroenterology 1999,
117:632–639.
4. Everhart JE, Yeh F, Lee ET, Hill MC, Fabsitz R, Howard BV, Welty TK:
Prevalence of gallbladder disease in American Indian populations:
findings from the strong heart study. Hepatology 2002, 35:1507–1512.
5. Maurer KR, Everhart JE, Ezzati TM, Johannes RS, Knowler WC, Larson DL, Sanders
R, Shawker TH, Roth HP: Prevalence of gallstone disease in Hspanic
populations in the United States. Gastroenterology 1989, 96:487–492.
6. Everhart JE: Gallstones and ethnicity in the Americas. J Assoc Acad Minor
Phys 2001, 12:137–143.
7. Diehl AK, Stern MP, Ostrower VS, Friedman PC: Prevalence of clinical
gallbladder disease in Mexican-American, Anglo, and black women.
South Med J 1980, 73:438–441.
8. Stinton LM, Shaffer EA: Epidemiology of gallbladder disease: cholelithiasis
and cancer. Gut Liver 2012, 6:172–187.
9. Buch S, Schafmayer C, Volzke H, Seeger M, Miquel JF, Sookoian SC, Egberts
JH, Arlt A, Pirola CJ, Lerch MM, John U, Franke A, Von KO, Brosch M,
Nothnagel M, Kratzer W, Boehm BO, Broring DC, Schreiber S, Krawczak M,
Hampe J: Loci from a genome-wide analysis of bilirubin levels are associ-
ated with gallstone risk and composition. Gastroenterology 2010,
139:1942–1951.
10. Johnson AD, Kavousi M, Smith AV, Chen MH, Dehghan A, Aspelund T, Lin
JP, van Duijn CM, Harris TB, Cupples LA, Uitterlinden AG, Launer L, Hofman
A, Rivadeneira F, Stricker B, Yang Q, O'Donnell CJ, Gudnason V, Witteman
JC: Genome-wide association meta-analysis for total serum bilirubin
levels. Hum Mol Genet 2009, 18:2700–2710.
11. Krawczyk M, Wang DQ, Portincasa P, Lammert F: Dissecting the genetic
heterogeneity of gallbladder stone formation. Semin Liver Dis 2011, 31:157–172.
12. Renner O, Harsch S, Schaeffeler E, Winter S, Schwab M, Krawczyk M,
Rosendahl J, Wittenburg H, Lammert F, Stange EF: A variant of the
SLC10A2 gene encoding the apical sodium-dependent bile acid trans-
porter is a risk factor for gallstone disease. PLoS One 2009, 4:e7321.
13. Stokes CS, Krawczyk M, Lammert F: Gallstones: environment, lifestyle and
genes. Dig Dis 2011, 29:191–201.
14. Gilat T, Feldman C, Halpern Z, Dan M, Bar-Meir S: An increased familial fre-
quency of gallstones. Gastroenterology 1983, 84:242–246.
15. Attili AF, De Santis A, Attili F, Roda E, Festi D, Carulli N: Prevalence of
gallstone disease in first-degree relatives of patients with cholelithiasis.
World J Gastroenterol 2005, 11:6508–6511.
16. Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU:
Genetic and environmental influences on symptomatic gallstone disease: a
Swedish study of 43,141 twin pairs. Hepatology 2005, 41:1138–1143.
17. Kurzawski M, Juzyszyn Z, Modrzejewski A, Pawlik A, Wiatr M, Czerny B,
Adamcewicz R, Drozdzik M: Apolipoprotein B (APOB) gene polymorphism
in patients with gallbladder disease. Arch Med Res 2008, 38:360–363.
18. Katsika D, Magnusson P, Krawczyk M, Grunhage F, Lichtenstein P, Einarsson
C, Lammert F, Marschall HU: Gallstone disease in Swedish twins: risk is
associated with ABCG8 D19H genotype. J Intern Med 2010, 268:279–285.
19. Juvonen T, Savolainen MJ, Kairaluoma MI, Lajunen LH, Humphries SE, Kes +
ñniemi YA: Polymorphisms at the apoB, apoA-I, and cholesteryl ester transfer
protein gene loci in patients with gallbladder disease. J Lipid Res 1995,
36:804–812.
20. Buch S, Schafmayer C, Volzke H, Becker C, Franke A, von Eller-Eberstein H, Kluck C,
Bassmann I, Brosch M, Lammert F, Miquel JF, Nervi F, Wittig M, Rosskopf D, Timm
B, Holl C, Seeger M, ElSharawy A, Lu T, Egberts J, Fandrich F, Folsch UR, Krawczak
M, Schreiber S, Nurnberg P, Tepel J, Hampe J: A genome-wide association scan
identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor
for human gallstone disease. Nat Genet 2007, 39:995–999.
21. Grunhage F, Acalovschi M, Tirziu S, Walier M, Wienker TF, Ciocan A,
Mosteanu O, Sauerbruch T, Lammert F: Increased gallstone risk in humans
conferred by common variant of hepatic ATP-binding cassette trans-
porter for cholesterol. Hepatology 2007, 46:793–801.22. Dumitrescu L, Carty CL, Taylor K, Schumacher FR, Hindorff LA, Ambite J-L, Ander-
son G, Best LG, Brown-Gentry K, Buzkova P, Carlson CS, Cochran B, Cole SA, Dev-
ereux RB, Duggan D, Eaton CB, Fornage M, Franceschini N, Haessler J, Howard BV,
Johnson KC, Laston S, Kolonel LN, Lee ET, MacCluer JW, Manolio TA, Pendergrass
SA, Quibrera M, Shohet RV, Wilkens LR, Haiman CA, Le Marchand L, Buyske S,
Kooperberg C, North KE, Crawford DC: Genetic determinants of lipid traits in di-
verse populations from the Population Architecture using Genomics and Epi-
demiology (PAGE) study. PLoS Genet 2011, 7:e1002138.
23. Matise TC, Ambite JL, Buyske S, Carlson CS, Cole SA, Crawford DC, Haiman CA,
Heiss G, Kooperberg C, Le Marchand L, Manolio TA, North KE, Peters U, Ritchie
MD, Hindorff LA, Haines JL: The next PAGE in understanding complex traits:
design for the analysis of Population Architecture Using genetics and
Epidemiology (PAGE) study. Am J Epidemiol 2011, 174:849–859.
24. von Kampen O, Buch S, Nothnagel M, Azocar L, Molina H, Brosch M, Erhart
W, von Schonfels W, Egberts J, Seeger M, Arlt A, Balschun T, Franke A, Lerch
MM, Mayerle J, Kratzer W, Boehm BO, Huse K, Schniewind B, Tiemann K,
Jiang ZY, Han TQ, Mittal B, Srivastava A, Fenger M, Jorgensen T, Schirin-
Sokhan R, Tonjes A, Wittenburg H, Stumvoll M, Kalthoff H, Lammert F, Tepel
J, Puschel K, Becker T, Schreiber S, Platzer M, Volzke H, Krawczak M, Miquel
JF, Schafmayer C, Hampe J: Genetic and functional identification of the
likely causative variant for cholesterol gallstone disease at the ABCG5/8
lithogenic locus. Hepatology 2013, 57:2407–2417.
25. National Center for Health Statistics: Plan and Operation of the Third National
Health and Nutrition Examination Survey, 1988–94. Hyattsville, MD: National
Center for Health Statistics; 1994. Vital and Health Statistics, Series 1:
Programs and Collection Procedures, no. 32) (DHHS publication no. (PHS)
94-1308) (GPO no. 017-022-01260-0.
26. Pendergrass S, Dudek S, Crawford D, Ritchie M: Synthesis-View: visualization
and interpretation of SNP association results for multi-cohort, multi-
phenotype data and meta-analysis. Bio Data Mining 2010, 3:10.
27. Johnson AD, Handsaker RE, Pulit S, Nizzari MM, ODonnell CJ, de Bakker PI:
SNAP: a web-based tool for identification and annotation of proxy SNPs
using HapMap. Bioinformatics 2008, 24:2938–2939.
28. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, Penninx
BW, Janssens AC, Wilson JF, Spector T, Martin NG, Pedersen NL, Kyvik KO, Kaprio
J, Hofman A, Freimer NB, Jarvelin MR, Gyllensten U, Campbell H, Rudan I,
Johansson A, Marroni F, Hayward C, Vitart V, Jonasson I, Pattaro C, Wright A,
Hastie N, Pichler I, Hicks AA, Falchi M, Willemsen G, Hottenga JJ, de Geus EJ,
Montgomery GW, Whitfield J, Magnusson P, Saharinen J, Perola M, Silander K,
Isaacs A, Sijbrands EJ, Uitterlinden AG, Witteman JC, Oostra BA, Elliott P,
Ruokonen A, Sabatti C, Gieger C, Meitinger T, Kronenberg F, Döring A, Wichmann
HE, Smit JH, McCarthy MI, van Duijn CM, Peltonen L, ENGAGE Consortium: Loci
influencing lipid levels and coronary heart disease risk in 16 European
population cohorts. Nat Genet 2009, 41:47–55.
29. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC,
Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F,
Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H,
Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA:
Newly identified loci that influence lipid concentrations and risk of coronary
artery disease. Nat Genet 2008, 40:161–169.
30. The 1000 Genomes Project Consortium: A map of human genome
variation from population-scale sequencing. Nature 2010, 467:1061–1073.
31. Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A: Sterol trans-
porter adenosine triphosphate−binding cassette transporter G8, gallstones,
and biliary cancer in 62,000 individuals from the general population.
Hepatology 2011, 53:640–648.
32. Kuo KK, Shin SJ, Chen ZC, Yang Y-HC, Yang JF, Hsiao PJ: Significant associ-
ation of ABCG5 604Q and ABCG8 D19H polymorphisms with gallstone
disease. Br J Surg 2008, 95:1005–1011.
33. Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, Boehnke M:
Genome-wide association studies in diverse populations. Nat Rev Genet 2010,
11:356–366.
34. Zondervan KT, Cardon LR: Designing candidate gene and genome-wide
case–control association studies. Nat Protocols 2007, 2:2492–2501.
doi:10.1186/1471-2350-14-120
Cite this article as: Goodloe et al.: Lipid trait-associated genetic variation
is associated with gallstone disease in the diverse Third National Health
and Nutrition Examination Survey (NHANES III). BMC Medical Genetics
2013 14:120.
